Evolution of Treatment for Diabetic Nephropathy: Historical Progression From RAAS Inhibition and Onward

被引:9
作者
Blumenthal, Samuel S. [1 ]
机构
[1] Med Coll Wisconsin, Div Nephrol, Milwaukee, WI 53226 USA
关键词
type 2 diabetes mellitus; diabetic nephropathy; diabetic kidney disease; renal disease; HEPATOCYTE GROWTH-FACTOR; GLYCATION END-PRODUCTS; BLOOD-PRESSURE CONTROL; DIETARY-PROTEIN RESTRICTION; CORONARY-ARTERY-DISEASE; MATRIX GENE-EXPRESSION; CHRONIC RENAL-DISEASE; FACTOR-BETA; CARDIOVASCULAR OUTCOMES; KIDNEY-FUNCTION;
D O I
10.3810/pgm.2011.11.2506
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The past 2 decades have brought rapid advances in treatment options for chronic kidney disease; however, even with the best treatment, the decline of renal function and progression to end-stage renal disease (ESRD) continues in a significant number of patients. The prognosis of patients with diabetes and ESRD is grim, with < 50% of patients surviving beyond 5 years after diagnosis. Therefore, early recognition and optimal use of available interventions are essential, and research into newer therapeutic targets is needed. This article will review recent advances in our understanding of renal pathophysiology, summarize the evidence to date supporting current treatment options for diabetic nephropathy, and highlight new options that lie on the horizon for the treatment of diabetic kidney disease.
引用
收藏
页码:166 / 179
页数:14
相关论文
共 114 条
  • [81] Rodbard Helena W, 2007, Endocr Pract, V13 Suppl 1, P1
  • [82] Rodríguez-Morán M, 2005, CLIN NEPHROL, V64, P91
  • [83] Ruggenenti P, 1997, LANCET, V349, P1857
  • [84] Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
    Ruggenenti, P
    Perna, A
    Gherardi, G
    Garini, G
    Zoccali, C
    Salvadori, M
    Scolari, F
    Schena, FP
    Remuzzi, G
    [J]. LANCET, 1999, 354 (9176) : 359 - 364
  • [85] Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial
    Ruggenenti, P
    Perna, A
    Gherardi, G
    Gaspari, F
    Benini, R
    Remuzzi, G
    [J]. LANCET, 1998, 352 (9136) : 1252 - 1256
  • [86] Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
    Ruggenenti, P
    Perna, A
    Gherardi, G
    Benini, R
    Remuzzi, G
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (06) : 1155 - 1165
  • [87] Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial
    Ruggenenti, P
    Perna, A
    Loriga, G
    Ganeva, M
    Ene-Iordache, B
    Turturro, M
    Lesti, M
    Perticucci, E
    Chakarski, IN
    Leonardis, D
    Garini, G
    Sessa, A
    Basile, C
    Alpa, M
    Scanziani, R
    Sorba, G
    Zoccali, C
    Remuzzi, G
    [J]. LANCET, 2005, 365 (9463) : 939 - 946
  • [88] Sakata H, 1996, CELL GROWTH DIFFER, V7, P1513
  • [89] Combined Paracrine and Endocrine AAV9-mediated Expression of Hepatocyte Growth Factor for the Treatment of Renal Fibrosis
    Schievenbusch, Stephanie
    Strack, Ingo
    Scheffler, Melanie
    Nischt, Roswitha
    Coutelle, Oliver
    Hoesel, Marianna
    Hallek, Michael
    Fries, Jochen W. U.
    Dienes, Hans-Peter
    Odenthal, Margarete
    Buening, Hildegard
    [J]. MOLECULAR THERAPY, 2010, 18 (07) : 1302 - 1309
  • [90] Profiling of anti-fibrotic signaling by hepatocyte growth factor in renal fibroblasts
    Schievenbusch, Stephanie
    Strack, Ingo
    Scheffler, Melanie
    Wennhold, Kerstin
    Maurer, Julia
    Nischt, Roswitha
    Dienes, Hans Peter
    Odenthal, Margarete
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 385 (01) : 55 - 61